1. Home
  2. DPRO vs TENX Comparison

DPRO vs TENX Comparison

Compare DPRO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$5.02

Market Cap

272.6M

Sector

Industrials

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.44

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPRO
TENX
Founded
1998
1967
Country
Canada
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.6M
317.8M
IPO Year
2019
2001

Fundamental Metrics

Financial Performance
Metric
DPRO
TENX
Price
$5.02
$13.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$15.00
$29.67
AVG Volume (30 Days)
2.1M
923.9K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$158.69
N/A
Revenue Next Year
$131.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.96
$5.67
52 Week High
$14.37
$18.38

Technical Indicators

Market Signals
Indicator
DPRO
TENX
Relative Strength Index (RSI) 37.12 61.96
Support Level $4.35 $13.16
Resistance Level $5.69 $14.15
Average True Range (ATR) 0.47 0.80
MACD -0.17 0.30
Stochastic Oscillator 6.49 83.56

Price Performance

Historical Comparison
DPRO
TENX

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: